These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19075765)

  • 1. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
    Gwaltney SL
    Curr Top Med Chem; 2008; 8(17):1545-52. PubMed ID: 19075765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of vildagliptin from an internal disease specialists point of view].
    Kožnarová R
    Vnitr Lek; 2013 Apr; 59(4):322-4. PubMed ID: 23711060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
    Ito H; Wajima T; Yamaguchi M; Mimori N; Sekiguchi K
    Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):299-308. PubMed ID: 21079371
    [No Abstract]   [Full Text] [Related]  

  • 4. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
    Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.
    Sehra D; Sehra S
    J Assoc Physicians India; 2011 Nov; 59():744; author reply 744. PubMed ID: 22616349
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 7. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
    Scherbaum WA
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
    [No Abstract]   [Full Text] [Related]  

  • 8. DPP-4 inhibitors: what may be the clinical differentiators?
    Gerich J
    Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
    Takayanagi R; Uchida T; Kimura K; Yamada Y
    Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus.
    van Poppel PC; Gresnigt MS; Smits P; Netea MG; Tack CJ
    Diabetes Res Clin Pract; 2014 Mar; 103(3):395-401. PubMed ID: 24485397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vildagliptin].
    Iwamoto Y
    Nihon Rinsho; 2011 May; 69(5):865-70. PubMed ID: 21595273
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
    Nabeno M; Akahoshi F; Kishida H; Miyaguchi I; Tanaka Y; Ishii S; Kadowaki T
    Biochem Biophys Res Commun; 2013 May; 434(2):191-6. PubMed ID: 23501107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
    Saisho Y; Itoh H
    Diabet Med; 2013 Apr; 30(4):e149-50. PubMed ID: 23323612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 19. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.